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ABSTRACT
A rapid and sensitive stability indicating HPLC method has been developed and validated for the determination of buprenorphine (BPN) in transdermal patch. Chromatographic separation was achieved isocratically on an XBridgeTM Shield RP18 column
with a mobile phase of acetonitrile / 0.063 M ammonium bicarbonate buffer (pH 9.5) (58:42, v/v) at the flow rate of 1.5 mL/min
with UV absorbance monitoring at 230 nm. The system performance was evaluated and the result showed that BPN and degradation products were separated. Buprenorphine was subjected to neutral, acidic and basic hydrolysis as well as chemical oxidation to
evaluate the specificity. The calibration curve of buprenorphine was linear in the range of 30~70 μg/mL (r = 0.9999, n = 5). The
values of RSD (%) for the intra-day and inter-day precision ranged from 0.04 to 0.22 and 0.65 to 0.88%, respectively. The average of
the recovery percentage ranged from 98.86 to 99.36%. The detection limit (DL) and quantitation limit (QL) for buprenorphine were
0.008 and 0.024 μg/mL, separately. The robustness of this method was also evaluated on the small fluctuations of pH in the mobile
phase, the mobile phase compositions, and the flow rate. The results of stability studies showed the hydrolysis reaction of buprenorphine followed zero-order kinetics model in acidic and basic environment and followed first-order kinetics model in the presence of
hydrogen peroxide. This analytical method was successfully applied to the determination of buprenorphine in transdermal patch
and can be used for routine quality control work.
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INTRODUCTION
Buprenorphine (Figure 1) is a semisynthetic opioid
derivative, closely related to morphine and congener
alkaloids, which is obtained from thebaine after a sevenstep chemical process (1). Buprenorphine has been used
to control cancer pain and can be given by several administration routes. Parenteral and sublingual preparations
were initially used (2). In recent years, the formulation
of buprenorphine in transdermal matrix patch has been
successfully developed (3).
An opioid derivative could form an ion pair between
its basic nitrogen and a negatively charged group, such
as from sodium 1-heptanesulfonate. Thus, it could be
determined by using the ion-pair reversed-phase HPLC.
However, the retention time of buprenorphine obtained in
USP 30 (4) and EP 5.0 (5) are long and the sensitivity of the
recommended methods are unsatisfied.
* Author for correspondence. Tel: +886-4-22053366 ext. 5608;
Fax: +886-4-22078083; E-mail: professor.kuo@gmail.com

The XBridgeTM column was designed to overcome
some limitations of classical silica based reversed-phase
HPLC columns with a wider pH limit of 1-12. Buprenorphine is a weak base with a pKa of 8.24 and therefore
alkaline environment will favor the unionized form of the
drug and offer a symmetrical peak shape (6,7).
The objective of this study was to develop an effective and sensitive stability indicating method for transdermal buprenorphine patch by using the XBridgeTM
column and HPLC-UV detector and to validate this
method according to the compendious guidelines (8,9).
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Figure 1. Structure of buprenorphine .
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MATERIALS AND METHODS(8-12)
I. Materials
Buprenorphine, 21-cyclopropyl-7α-[(S)-1-hydroxy1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine, was purchased from Tasmanian Alkaloid
(Australia). The USP reference standard of buprenorphine related compound A (impurity), 21-[3-(1-propenyl)]-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14endo-ethano-6,7,8,14-tetrahydrooripavine, was purchased
from the US Pharmacopeial Convention(4).
Polystyrene-block-polyisoprene-bolck-polystyrene
(SIS, 17 wt.% styrene), rosin ester (KE-311), and paraffin oil (puriss., meets analytical specification of Ph. Eur.,
BP, viscous liquid) were purchased from Sigma-Aldrich
Co., Arakawa Chemical Co., and Riedel-de Haën Co.,
respectively. All other solvents and reagents were of
analytical or HPLC grade.
II. HPLC Instrumentation and Chromatographic Conditions
The analyses of the samples in this study were
performed on a Hewlett-Packard 1100 HPLC system
(AGILENT Technologies) which is equipped with a
G1311A quaternary pump, a G1313A automatic injector, a
G1314A photodiode array detector, a Chemstation version
A.07 data acquisition software, and a G1316A column
oven.
The chromatographic conditions were as follows:
separations were carried out at 30°C on an XBridgeTM
Shield RP18 column (4.6 × 75 mm, 2.5 μm; Waters), the
mobile phase consisted of acetonitrile / 0.063 M ammonium bicarbonate buffer (pH 9.5) (58:42, v/v) at the flow
rate of 1.5 mL/min. The mobile phase was degassed in an
ultrasonic bath and filtered by a Millipore vacuum filter
system equipped with a 0.22 μm filter prior to use. The
injection volume was 20 μL for each analysis. The chromatography was monitored by the absorbance at 230 nm.
III. Preparation of Stock and Standard Solution
Stock solution of buprenorphine (0.5 mg/mL) was
prepared in methanol. Standard solution of buprenorphine (50 μg/mL) was prepared by diluting the stock
solution of buprenorphine with the mobile phase. The
peak shape of standard solution of buprenorphine was
measured by the photodiode array detector at wavelengths of 210, 230, 254, and 288 nm.
IV. System Suitability
Stock solution of buprenorphine impurity (50 μg/
mL) was prepared in methanol. An aliquot of 5 mL stock
solutions of buprenorphine and its impurity were individually placed into a 50 mL volumetric flask and made
to volume with the mobile phase for system suitability

study. This solution was analyzed for six times to obtain
the parameters of system suitability.
V. Specificity
Sample solution of buprenorphine (50 μg/mL) was
used to evaluate the specificity of this analytical method
under the neutral, acidic, and basic conditions, while
stock solution of buprenorphine was used to evaluate the
specificity under the chemical oxidative condition at 80°C
over certain period of time. The media and the reaction
times were as follows: (a) 0.1 M pH 7.0 phosphate buffer
solution for 120 hours, (b) 1.0 M HCl solution for 6 hours,
(c) 1.0 M NaOH solution for 24 hours, and (d) 10% H 2O2
solution for 2 hours. All samples were neutralized and
diluted before analysis. Each solution was analyzed in
duplicate.
VI. Linearity and Range
By appropriate dilution with the mobile phase, five
different concentrations of the standard solutions of
buprenorphine from 30 to 70 μg/mL were prepared. The
solutions were measured, separately, for five times according to the chromatographic conditions previously given.
VII. Precision
The intra-day and inter-day precision were determined by analyzing the samples of buprenorphine at the
concentrations of 30, 50, and 70 μg/mL. Each sample
was analyzed for five times on the same day. They were
studied over three consecutive days and each intra-day
analysis was performed by different operators.
VIII. Accuracy
The adhesive solution was made by adding SIS, rosin
ester and paraffin oil in a ratio of 45:55:10 into coating
solvent ethyl acetate and mixing on a reciprocal shaker at
250 rpm at room temperature(13). Three adhesive solutions
containing 1.5, 2.5, and 3.5 mg of buprenorphine, individually, were coated on the release liner and the adhesive films
were allowed to dry at 50°C for 20 minutes. They were
stored at room temperature for 10 minutes. The backing
sheets were then placed on the dry adhesive to prepare the
transdermal buprenorphine patches.
Each patch was transferred into a 50 mL volumetric flask and made to volume with the mobile phase.
They were sonicated at the 60°C for 1 hour. All of them
were filtered through a 0.22 μm filters. Each sample was
analyzed for five times.
IX. Detection Limit and Quantitation Limit
By appropriate dilution of the stock solution of
buprenorphine with the mobile phase, three standard
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solutions of 0.25, 0.5, and 1 µg/mL were prepared. Each
standard solution was assayed for three times. Linear
regression analysis was performed to obtain the regression equation. The detection limit (DL) and the quantitation limit (QL) were calculated from DL = 3.3 σ/S , and
QL = 10 σ/S
Where σ is the standard deviation of the Y-intercept
and S is the slope of the calibration curve.

at the 288 nm. When the standard solution of buprenorphine was measured at 210, 230, 254, and 288 nm individually, all the peak shapes detected at different wavelengths were acceptable (see Figure 2(B)). Finally, the
adopted wavelength was set at 230 nm as the sensitivity
was concerned.

X. Robustness

The parameters of system suitability of buprenorphine and its impurity showed that the peaks were
completely separated. The system suitability data were
listed in Table 1 and the chromatogram of buprenorphine
and its impurity was shown in Figure 3.

The influence of deliberate small variations of the
factors in the determination of buprenorphine were
examined in order to estimate the robustness of the
proposed method. The factors to be examined were: pH
in the mobile phase, the mobile phase compositions, and
the flow rate. One factor was changed at a time and the
analytical values were examined accordingly (14).
XI. Stability Studies

II. System Suitability

mAU

(A)
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80

(I) Acidic Stability
A sealed sample bottle contained 180 mL 0.1 M HCl
and 20 mL stock solution of buprenorphine were mixed
in a sealed sample bottle and stored at 60°C in the oven.
An aliquot of 5 mL was taken out every day and kept in a
freezer.
(II) Basic Sstability
A sealed sample bottle contained 180 mL 0.1 M
NaOH and 20 mL stock solution of buprenorphine were
mixed in a sealed sample bottle and stored at 80°C in the
oven. An aliquot of 5 mL was taken out every 4 hours
and kept in a freezer.
(III) Chemical Oxidative Stability
A sealed sample bottle contained 200 mL 10% H 2O2
and 200 mL stock solution of buprenorphine were mixed
in a sealed sample bottle and stored at 60°C in the oven.
An aliquot of 5 mL was taken out every half an hour and/
or one hour and kept in a freezer.
Each sample was analyzed for three times in order to
obtain the kinetic profiles.
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Figure 2. (A) Absorption spectrum of buprenorphine in the mobile
phase. (B) The standard solution of buprenorphine was detected at
the wavelengths of 210, 230, 254, and 288 nm, simultaneously.

Table 1. The system suitability evaluation of the HPLC method
developed

RESULTS AND DISCUSSION
I. Development of the HPLC Method
The chromatograms and absorption spectrum of
buprenorphine in this study were shown in Figure 2. The
retention time of buprenorphine was about 7.8 minutes.
The maximal absorption was at the 210 nm. The wavelength of the detection adopted in USP 30 and EP 5.0 was

buprenorphine

buprenorphine
impurity

Retention time (min）

7.80

8.80

K’ (capacity factor)

16.20

18.03

N (theoretical plate)

9821

9764

T (tailing factor)

1.18

1.10

Rs (resolution)

2.50
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III. Specificity
The percentage of remaining concentration of
buprenorphine in specificity studies were given in Table
2.
Chromatograms of specificity studies were given
in Figure 4. When the stock solution of buprenorphine
was exposed to neutral hydrolysis, no decomposition
was observed which indicated it was quite stable under
the neutral hydrolysis condition (Figure 4 (A)). However,
when the stock solutions of buprenorphine were exposed
to acidic, basic, or oxidative media as described in Table
2, the percentage of remaining concentration were about
43, 75, and 30%, respectively (Figure 4 (B)-(D)). The
other decomposed products were completely separated
from buprenorphine indicating that the developed method
could be useful to separate buprenorphine from its degradation products.

to 0.22% and 0.65 to 0.88%, respectively. The results
revealed good precision for the proposed analytical
method (see Table 3).
VI. Accuracy
The recovery of the transdermal buprenorphine
patches were calculated from: Recovery (%) = [Ct / Ca]
× 100
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IV. Linearity and Range
mAU

Linear relationship was observed in the calibration
curve in the range of 30~70 μg/mL. The regression equation was found as y = 13371x - 4481.6 (r = 0.9999, n = 5),
where y is the peak area of buprenorphine and x is the
concentration of the measured solution in μg/mL.
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V. Precision
mAU

The intra-day (n = 5) and inter-day (n = 15, three
different days) precision were expressed as relative
standard deviation (RSD). The values of RSD for the
intra-day and inter-day precision were ranged from 0.04
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Figure 3. The chromatogram of buprenorphine and its impurity.

Figure 4. Chromatograms corresponding to buprenorphine solution
underwent (A) neutral hydrolysis (B) acidic hydrolysis (C) basic
hydrolysis (D) chemical oxidation.

Table 2. Remaining concentration of buprenorphine in specificity studies
Condition

Time (hr)

The percentage of remaining concentration (%)

Neutral hydrolysis

0.1 M pH 7.0 phosphate buffer, 80°C

120

98.97

Acidic hydrolysis

1.0 M HCl, 80°C

6

42.86

Basic hydrolysis

1.0 M NaOH, 80°C

24

75.26

Chemical oxidation

10% H2O2, 80°C

2

30.26
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where Ct is the concentration of buprenorphine
found and Ca is the concentration of buprenorphine
added to the patch.
The average recovery percentage ranged from 98.86
to 99.36%, indicating that the proposed analytical method
was accurate (Table 4).
VII. Detection Limit and Quantitation Limit
By calculating the analytical results, the standard
deviation of the Y-intercept (σ) and the slope of the calibration curve (S) were 30.54 and 12701, respectively. (see
Table 5). The detection limit (DL) and quantitation limit
(QL) of buprenorphine were 0.008 and 0.024 μg/mL,
separately.
VIII. Robustness
The results for the robustness study were presented in Table 6. It showed that the HPLC performance

Table 3. The results of the intra-day and inter-day precision
Actual concentration
(μg/mL)

Intra-day

30

50

70

day 1 (n=5) RSD (%)

0.08

0.22

0.15

day 2 (n=5) RSD (%)

0.04

0.06

0.12

day 3 (n=5) RSD (%)

0.19

0.15

0.06

(n=15) RSD (%)

0.88

0.65

0.77

Inter-day

were still acceptable by small variations of the selected
factors.
IX. Stability Studies
The stability profiles were obtained from the results
of the stability studies (see Figure 5). Both of the kinetics in Figure 5(A) and 5(B) followed the zero-order kinetics model and the rate constants were 0.13 μg/mL•hr at
60°C and 0.76 μg/mL•hr at 80°C, respectively. The reaction of buprenorphine in hydrogen peroxide followed the
first-order kinetics model and the rate constant was 0.09
1/hr at 60°C as shown in Figure 5(C).

CONCLUSIONS
A rapid and effective stability indicating method has
been validated according to the compendious guidelines.
It can be applied to the routine analysis of buprenorphine
in transdermal patch. This proposed reversed-phase HPLC
method has been evaluated for the system suitability, specificity, linearity and range, precision, accuracy, detection
limit, quantitation limit, robustness, and stability studies.
The advantages of this method are as follows: the
peak shape is sharp and symmetrical. The retention time
of buprenorphine by this method is about 7.8 minutes,
comparing to 13 or 15 minutes by the recommended methods in the USP 30 or EP 5.0, respectively. The peak height
of buprenorphine at 230 nm is about five times as high as
that at 288 nm. Therefore, a more sensitive method can
be expected. Potentially, this method can be employed in
the analysis of the quality control and skin permeation of
buprenorphine in the transdermal patch in the future.

Table 4. The results of recovery studies
Concentration of buprenorphine
added (μg/mL)

Concentration of buprenorphine
found (μg/mL)

RSD (%) (n = 5)

Recovery of
buprenorphine (%)

30

29.83

0.44

99.25

50

49.53

0.24

98.86

70

69.69

0.30

99.36

Table 5. Data for calculating the detection limit and quantitation limit
0.25 (μg/mL)

0.50 (μg/mL)

1.00 (μg/mL)

slope

Y-intercept

Calibration 1

3020

6018

12408

12555

175.00

Calibration 2

2999

6140

12598

12815

230.00

Calibration 3

2945

6161

12502

12734

225.50

Average

2988

6106

12503

12701

210.17

SD

38.69

77.22

95.00

—

30.54
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Table 6. The robustness evaluation of the HPLC method developed
K’
(capacity factor)

N
(theoretical plate)

T
(tailing factor)

Rs
(resolution)

9.3

17.99

7766

1.09

2.25

9.5

17.59

7665

1.07

2.09

9.7

17.42

7774

1.10

2.11

56/44

21.17

7802

1.08

2.34

58/42

17.59

7665

1.07

2.09

60/40

14.70

7423

1.09

1.81

1.4

17.72

7657

1.08

2.08

1.5

17.59

7665

1.07

2.09

1.6

17.56

7652

1.08

2.09

Chromatographic change factor
A: pH in the mobile phase

B: mobile phase (ACN/Buffer)

C: flow rate (mL/min)

(A)

3

y = -0.13x + 37.80

40

R2 = 0.996

30

Log Conc.

Conc. (µg/mL)

50

20
10
0

0

50

100

150

200

250

Conc. (µg/mL)

(B)

R2 = 0.983

2
1
0

0

2

4

6

8

10

12

Time (hr)

Time (hr)
50

y = -0.04x + 2.28

(C)

y = -0.76x + 39.09

40

R2 = 0.993

30
20
10
0

0

10

20

30

40

Time (hr)
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